Information Provided By:
Fly News Breaks for July 26, 2019
Jul 26, 2019 | 11:26 EDT
Piper Jaffray analyst Joseph Catanzaro maintained an Overweight rating and $8 price target on Ocular Therapeutix after the company's Dextenza was issued a J-code to become effective October 2019, one quarter ahead of expectations. The analyst noted that the J-code will "allow for reimbursement of Dextenza insertion in the in-office setting," which he called "a clearly attractive proposition for physicians."
News For OCUL From the Last 2 Days
There are no results for your query OCUL